The Vel antigen is present on red blood cells (RBCs) from all humans except rare Vel-negative individuals who can form antibodies to Vel in response to transfusion or pregnancy. These antibodies may cause severe hemolytic reactions in blood recipients. We combined SNP profiling and transcriptional network modeling to link the Vel-negative phenotype to SMIM1, located in a 97-kb haplotype block on chromosome 1p36. This gene encodes a previously undiscovered, evolutionarily conserved transmembrane protein expressed on RBCs. Notably, 35 of 35 Vel-negative individuals were homozygous for a frameshift deletion of 17 bp in exon 3. Functional studies using antibodies raised against SMIM1 peptides confirmed a null phenotype in RBC membranes, and SMIM1 overexpression induced Vel expression. Genotype screening estimated that ~1 of 17 Swedish blood donors is a heterozygous deletion carrier and ~1 of 1,200 is a homozygous deletion knockout and enabled identification of Vel-negative donors. Our results establish SMIM1 as a new erythroid gene and Vel as a new blood group system.
Human RBCs carry functionally important proteins and glycoproteins on their surfaces. Allelic variation in the underlying genes determines the presence or absence of antigenic structures on these molecules and, in turn, transfusion and transplant compatibility between individuals.
The Vel-negative blood group phenotype was described in 1952 when Sussman et al. reported a patient who suffered an acute intravascular hemolytic episode after a blood transfusion 1 . The patient made antibodies that reacted with all RBCs tested except her own. The newly defined antigen was named Vel. Subsequent reports of hemolytic reactions after transfusion of Vel-positive RBCs to Velnegative individuals with antibody to Vel and of hemolytic disease in the newborns of Vel-negative mothers have established Vel as a clinically important blood group antigen 2, 3 .
Since its description, the Vel antigen has eluded molecular identification. Population studies estimate the prevalence of Vel-negative individuals at ~1 in 4,000 in Europe 2 , but the prevalence is somewhat higher (~1 in 1,700) in northern Scandinavia 2, 4 . Family studies suggest that the Vel-negative phenotype is inherited as an autosomal recessive trait, but no locus has been found 4, 5 . Similarly, efforts to identify a Vel carrier molecule have been inconclusive 6 . Hence, identification of Vel-negative blood donors who can provide compatible blood to Vel-negative patients with antibody to Vel relies on typing with scarce polyclonal sera from immunized individuals, as monoclonal reagents do not exist.
Because of its presumed inheritance pattern and its higher prevalence in northern Scandinavia (a sparsely populated and historically isolated region), we hypothesized that the Vel-negative phenotype could be caused by a homozygous founder mutation surrounded by an identifiable SNP signature. We therefore performed SNP profiling in 20 Vel-negative individuals (predominantly Swedish; Supplementary Table 1) using microarrays (2.44 million SNPs).
We identified SNPs that segregated with the Vel-negative phenotype by requiring a homozygous and identical SNP genotype in five Vel-negative siblings from two families and a different genotype in their Vel-positive siblings (Fig. 1a) . This filter identified 8,780 SNPs distributed across the genome. To test which of the segregating SNPs were enriched among Vel-negative individuals, we compared minor allele frequencies among the 15 remaining non-related Vel-negative individuals to background frequencies calculated across 379 whole genome-sequenced individuals of European ancestry from the 1000 Genomes Project 7 . Notably, this comparison identified 25 highly enriched SNPs in a 97-kb haplotype block on chromosome 1p36, where all 20 Vel-negative individuals showed the same SNP signature (Fig. 1b and Supplementary Table 2) .
The region at 1p36 contains five annotated genes ( Fig. 1c and Supplementary Table 3) . To prioritize these, we inferred a genomewide gene-regulatory network from 2,096 pre-existing gene expression profiles 8 of human bone marrow samples. In this analysis, SMIM1 (encoding small integral membrane protein 1) stood out, as its network neighborhood was dominated by known blood group genes and erythroid genes (Fig. 2) . Furthermore, SMIM1 has been predicted to be a transmembrane protein (UniProt; see URLs), contains binding sites for erythroid transcription factors such as GATA-1 (ref. 9) l e t t e r s (Supplementary Table 4) , is highly expressed in erythroleukemia cell lines (Supplementary Fig. 1 ) and is upregulated in human CD34 + hematopoietic progenitors cultured toward RBCs (Supplementary  Fig. 2 ). These results implicated SMIM1 as encoding an erythroid transmembrane protein, making it an ideal candidate gene.
According to the current human genome annotation, SMIM1 has four exons and encodes a 78-amino-acid protein (calculated weight of ~8.7 kDa). Computational sequence analysis predicted a type 1 transmembrane protein with an extracellular portion of ~50 amino acids containing potential O-glycosylation sites, a transmembrane domain containing a GXXXG motif (where X represents any amino acid) and a short intracellular tail but no other functional motifs (Fig. 3a,b and Supplementary Table 5) . Notably, protein sequence alignment found no homologs in humans, but 56 homologs were identified in 45 other species from primates to sea squirt. Cross-species genome sequence alignment uncovered a conserved GATA motif in primates and rodents, suggesting that SMIM1 is expressed in the erythroid lineage in higher mammals ( Fig. 3c and  Supplementary Fig. 3 ). Consistent with these bioinformatics results, we detected SMIM1 transcripts in total blood RNA by quantitative PCR (qPCR), both in Vel-positive and Vel-negative individuals (data not shown).
Sequencing of SMIM1 showed homozygosity for a 17-bp deletion in the coding region of exon 3 in all 20 Vel-negative individuals, whereas Vel-positive controls had consensus sequence ( Supplementary  Fig. 4 ). Because the deletion and its surrounding SNP signature is identical in all cases, it is likely a founder mutation. To ascertain that the deletion is truly associated with the Vel-negative phenotype, we collected DNA from 15 additional Vel-negative individuals (predominantly European; Supplementary Table 1 ). All cases in this independent validation cohort were homozygous for the same 17-bp deletion. Directed genotyping (Fig. 3d) Table 6 ), although the existence of alternative null alleles cannot be excluded.
The 17-bp deletion introduces a frameshift 5′ to the encoded transmembrane domain. With blood from a Vel-positive individual, 5′/3′ RACE showed that the wild-type transcript contains the complete coding sequence and an unannotated noncoding exon 1 (Supplementary Fig. 5 ). With blood from a Vel-negative individual, no capped and polyadenylated mRNA was captured, despite repeated attempts. With a known heterozygote, RACE yielded only the wildtype sequence. These data suggest that the mutant transcripts could be subject to degradation by mRNA surveillance mechanisms, as expected with the frameshift 10, 11 .
To explore the null phenotype, we synthesized peptides corresponding to the predicted extracellular domain of SMIM1 and raised rabbit polyclonal antibodies to these. Although the generated sera did not hemagglutinate RBCs, protein blotting under reducing conditions identified bands at ~9-10 and ~20 kDa for RBC membranes from Vel-positive blood and glycophorin A (GPA)-positive bone marrow cells. Human antibody to Vel showed similar reactivity with reduced Vel-positive membranes. Neither band was present in Vel-negative membranes or Vel-positive non-erythroid bone marrow cells (Fig. 4a-c) . Hence, SMIM1 is present on Vel-positive but not Vel-negative erythroid cells. Moreover, analysis of microarray profiles of human npg l e t t e r s tissues showed high SMIM1 expression in the bone marrow and lower levels in non-hematopoietic tissues (Supplementary Fig. 6 ).
The detection of two bands with antibody to SMIM1 (at approximately the calculated size and at two times this size) suggests that the protein forms reduction-resistant homodimers. This is consistent with the presence of the GXXXG motif, which mediates transmembrane dimerization via helix-helix association 12, 13 , as shown for GPA 14 . Additionally, protein blotting under non-reducing conditions showed broad reactivity, suggesting that SMIM1 forms disulfide-dependent complexes with itself or other as-yet-unidentified proteins (Fig. 4c) .
To verify that Vel depends on SMIM1, we overexpressed SMIM1 cDNA in the erythroleukemic cell line K562. In multiple experiments, we observed greater cell surface expression of Vel in SMIM1-transfected but not mock-or mutant-transfected cells by flow cytometry with human antibody to Vel, accompanied by greater protein expression, as shown with antibody to SMIM1 (Fig. 4d,e) . These results confirm SMIM1 as the gene underlying Vel antigen expression.
We compared Vel expression on RBCs from individuals heterozygous or negative for the deletion. Consistent with data from the transfection experiments, this analysis showed a strong correlation Figure 2 Identification of SMIM1 as a previously uncharacterized transmembrane protein expressed in erythroid cells. Because most blood group genes are expressed in erythroid cells, we prioritized the genes in the region at 1p36 by computing a genomewide gene-regulatory network for human hematopoiesis from 2,096 gene expression profiles of bone marrow samples 8 . Using a new computational tool, Ultranet 24 , we created a Gaussian Graphical Model, which is a sparse graph where nodes represent genes (n = 20,958) and vertices represent correlations in expression between genes that cannot be explained by confounding co-correlation with other observed genes. The network neighborhood of each gene was defined as the set of first-and seconddegree neighbor genes in the graph. Notably, the neighborhood of SMIM1 contained 17 of the 35 known blood group genes (red; χ 2 test for enrichment P < 1 × 10 −10 ) and was dominated by erythroid genes, including the erythropoietin receptor (EPOR), heme synthesis genes (UROD, HMBS, BLVRB, ALAD, ALAS1, CPOX, FECH), hemoglobin genes (HBD, HBM, HBQ1), erythroid transcription factors (GATA1, KLF1, GFI1B, TAL1, SOX6) and erythroid membrane proteins (numerous). By contrast, the neighborhoods of the other four candidate genes contained fewer genes and no erythroid genes or blood group genes (data not shown). SLC6A10P  TUBG1  DNAJA4  ACSL6  GFI1B  C17orf109  SPTA1  CTSE  ACHE  CDH1  TNXA  ABCC13  SPTB  HBBP1  TPM1  HBD  RAB6B  STEAP3  OR2W3  C5orf4  MINPP1  DARC  SLC2A1  PLEK2  RUNDC3A  TFR2  SLC22A4  STOM  APOC1  MOSPD1  ART4  GCLM  ADIPOR1  SLC40A1  PAQR9  FHDC1  NFE2  BSG  HEBP1  CD36  NPL  TMEM56  HBZ  KCNH2  MICAL2  DNAJC6  PINK1 GYPB  CR1L Homo sapiens
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Conservation npg l e t t e r s between Vel expression and SMIM1 deletion zygosity, most likely representing a gene dosage effect (Fig. 4f,g ).
Further biochemical studies confirmed that SMIM1 orients its N-terminal domain extracellularly and indicated that O-glycans may not be involved in the Vel epitope (Fig. 5) . This is consistent with in silico predictions (Supplementary Fig. 7) .
The Vel antigen has been elusive for 60 years. We show that allelic variation in SMIM1 defines the Vel blood group system and link the Vel-negative phenotype to a founder null allele. It is noteworthy that the genetic basis of the Vel-negative phenotype is identical in 35 individuals, as this contrasts with the heterogeneous backgrounds of other recently resolved blood groups [15] [16] [17] . This discovery enables the identification of rare Vel-negative blood donors by genotyping 18 . Screening for the 17-bp deletion was implemented at the Regional Blood Center in Lund, Sweden. So far, two new homozygotes were found and confirmed serologically as Vel negative, demonstrating how our findings facilitate the procurement of compatible blood for Vel-immunized patients who risk delayed transfusion support and worse outcomes 19 .
The identification of SMIM1 as an erythroid gene-encoding a novel transmembrane protein-raises intriguing questions. First, the protein's functional and molecular context awaits further exploration. Notably, there are similarities with glycophorins, especially GPA, a short, type 1 O-glycosylated transmembrane protein that forms is consistent with overall peptide degradation of the extracellular proteins. This effect was dose dependent for papain (P) and trypsin (T), as 1:100 dilutions of both enzymes (P 1:100 and T 1:100) did not affect reactivity; however, SMIM1 showed greater sensitivity to α-chymotrypsin (C and C 1:100). (c) Reprobing with antibody to GPA and GPB (clone E3, Sigma; 1:10,000 dilution) shows sensitivity to papain and α-chymotrypsin (although a relative resistance to trypsin) and also the expected shift in molecular weight after treatment with O-glycosidase (O), whereas no effect on SMIM1 reactivity is observed with O-glycosidase treatment. 14 . Second, conservation across species indicates an important function, particularly in higher mammal erythropoiesis. This raises the question of whether Vel-negative individuals, who are in fact human knockouts, exhibit as yet unrecognized hematological features. Third, it is conceivable that pathogens use SMIM1 as an invasion receptor, similar to how malarial parasites exploit other blood group carriers [20] [21] [22] . In fact, given our data (Fig. 5) and the similarities of SMIM1 with GPA, it is possible that SMIM1 represents the long-sought α-chymotrypsin-sensitive Plasmodium falciparum receptor 23 . Future studies will uncover the roles of SMIM1 in hematopoiesis and human disease. 
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Samples. Subject to ethical approval and informed consent, anonymized bone marrow samples from healthy volunteers, buffy coat waste material from routine blood donations and blood samples were obtained from various sources (Supplementary Table 1) . DNA panels for screening were anonymized collections of 520 unselected Swedish blood donors. No donors were approached solely for the purpose of this study.
Nucleic acid preparation. Genomic DNA was prepared with a modified salting-out procedure 25 and diluted to 100 ng/µl or isolated with the QIAamp DNA Blood Mini kit (Qiagen) and used undiluted. Total RNA was extracted from whole blood or cell lines using TRIzol LS (Life Technologies Europe).
SNP genotyping and SNP data analysis.
A total of 20 Vel-negative and 8 Vel-positive individuals were genotyped on HumanOmni 2.5M BeadChip microarrays probing 2,443,179 SNPs (Illumina; analysis performed at the Swegene Centre for Integrative Biology at Lund University (SCIBLU) genomics facility at Lund University). Genotypes were called in Illumina GenomeStudio (call rate >99.5% for all samples; four samples were genotyped twice with >99.3% concordance). To estimate background allele frequencies, we used whole-genome sequence data from 379 individuals of European ancestry from the 1000 Genomes Project 7 (because a high-resolution Swedish SNP data set was unavailable). Allele frequencies were compared by Fisher's exact test with P < 1 × 10 −8 set as the significance threshold. The linkage disequilibrium boundaries of the detected haplotype block were estimated from unfiltered genotype calls (Supplementary Table 2 ). These boundaries coincided with regions of high recombination rate in the 1000 Genomes Project CEU (Utah residents of Northern and Western European ancestry) population. SNP data for the identified region at 1p36 is given in Supplementary Table 2, but complete SNP data are not publicly available to protect the identity of the study participants, as individuals can be identified from SNP profiles.
Network modeling.
To infer gene-regulatory networks, we used a new highperformance tool (Ultranet 24 ), which enables computation of Gaussian Graphical Models at a genome scale. As input data, we used 2,096 Affymetrix U133A Plus 2 gene expression profiles of human bone marrow under different conditions 8 (NCBI Gene Expression Omnibus, accession GSE13159). Ultranet's λ parameter controls the sparsity of the network. In Figure 2 , λ = 0.75. Other reasonable values yielded concordant results.
Bioinformatic characterization of SMIM1. To predict the location of the transmembrane domain, we used nine different computational tools (Supplementary Table 5) . To find homologs, we searched the RefSeq non-redundant, Ensembl 68 and UniProtKB databases and retrieved alignment data from the UCSC Genome Browser (knownGene.exonAA table). BLASTP was performed using an E-value cutoff of 1. To search for conserved protein domains, we used NCBI Conserved Domains. To perform cross-species genome sequence alignment, we used the UCSC Genome Browser.
Chromatin immunoprecipitation and sequencing (ChIP-seq) data from the Encyclopedia of DNA Elements (ENCODE) 9 obtained via the UCSC Genome Browser were examined for transcription factor binding sites in SMIM1 (Supplementary Table 4) . Whole-exome sequence data from ESP were obtained from the NHLBI Exome Variant Server (Supplementary Table 6 ).
Genetic analysis of SMIM1. Genomic DNA from 35 Vel-negative and 10 Vel-positive samples was amplified with primers 388588int2f and 388588ex4r, which flank the SMIM1 ORF (Supplementary Table 7) . Amplified products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Life Technologies) on an ABI 3500 Dx Genetic Analyzer. Analyses were performed using CodonCode Aligner.
We developed genotyping methods to allow the discrimination of consensus or wild-type and deletion or mutant SMIM1 alleles ( Supplementary  Fig. 8 ). To screen blood donors, we used exon 3-specific PCR based on primers LOCex3f_screen and LOCex3r_screen (Supplementary Table 7) . Allele-specific PCR products of 178 bp (wild type) or 161 bp (mutant) were discriminated by agarose gel electrophoresis (Fig. 3c) .
Transcript analysis. Total RNA from whole blood or cell lines was converted to cDNA using the High-Capacity RNA-to-cDNA kit (Applied Biosystems). mRNA was amplified with the Expand High-Fidelity PCR system (Roche Diagnostics) using primers 388588cDNAf and 388588cDNAr, and the products were sequenced.
A TaqMan Gene Expression Assay (Hs01369635_g1 (Applied Biosystems), binding to the exon 3-exon 4 boundary) was used in quantitative RT-PCR for the detection of SMIM1 transcripts. Transcript quantities were normalized to those of human β-actin RNA (ACTB; Invitrogen assay 4333762F). All samples were run in triplicate and calibrated against the sample with the lowest C T value. Triplicates with ≥2 C T values of <40 were considered positive. mRNA was isolated from total blood RNA with the mRNA Isolation kit (Roche Diagnostics). RACE was performed with the FirstChoice RLM-RACE kit (Ambion). In 5′ RACE experiments, cDNA was synthesized with random or oligo(dT) primers. Gene-specific primers Vel 332R, Vel 355R and Vel 376R were used for nested PCR amplification together with the 5′ RACE forward primers provided in the kit. For 3′ RACE, cDNA was obtained with the provided adaptor, and nested PCR was performed with primers Vel 59F, Vel 176F and Vel 280F together with the 3′ RACE reverse primers. PCR products were analyzed by gel electrophoresis, isolated with the QIAquick Gel Extraction kit (Qiagen) and sequenced as described above. Primer sequences are shown in
